197results about "Mass spectrometric analysis" patented technology

The present invention relates to a mass spectrometric method for determining isomeric amino acid residues of a peptide and comprises the steps of: generating a list of peptide candidates using the amino acid lead sequence of the peptide, said lead sequence comprising positions of determined amino acid residues and at least one position with undetermined isomeric amino acid residues; predicting the collision cross section for each peptide candidate; comparing the predicted collision cross section of each peptide candidate with an experimentally determined collision cross section of the peptide and assigning the isomeric amino acid residues of the best matching peptide candidate to the isomeric amino acid residues of the peptide.

Provided herein are methods and kits for identifying a pregnancy-associated risk or condition in a subject. In embodiments, the methods include detecting levels of at least one biomarker in a substantially cell-free cervical fluid sample obtained from the subject. In embodiments, the methods include detecting levels of biomarkers in a cervical fluid sample including extravillous trophoblasts (EVT) obtained from the subject.

The invention relates to the quantitative measurement of steroidal compounds by mass spectrometry. In a particular aspect, the invention relates to methods for quantitative measurement of steroidal compounds from multiple samples by mass spectrometry.

The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and / or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and / or TBI risk stratification tool as part of assessing a subject's TBI status.

By adapting isotopic fingerprinting to the human body, experimental data revealed a specific chemical fingerprint of cancer, such as prostate cancer, "fossilized" in samples such as a patient's hair or nails. To interpret the isotopic chemical data of the samples, a predictive model was developed using machine learning algorithms and several dimensions to enable population differentiation. In several aspects, this provides a non-invasive method for cancer diagnosis, detection, or assessment developed by identifying the chemical fingerprint of cancer. TIFF2026509162000028.tif53159

Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample.

The instant disclosure relates to methods which employ the detection of ADP-D-glycero-β-D-manno-heptose (ADP-heptose) in a biological sample obtained from an individual. In certain aspects, the methods comprise administering a treatment to an individual in which ADP-heptose is detected. The methods may further comprise determining whether the individual has clonal hematopoiesis of indeterminate potential (CHIP) and circulating ADP-heptose.

This invention provides compositions and treatment methods for reducing hyperphenylalaninemia. [Solution] A genetically modified bacterium is provided, comprising: a) one or more genes encoding phenylalanine ammonia lyase (PAL), which are operably linked to a promoter that is not naturally associated with the PAL gene and can be directly or indirectly induced; b) one or more genes encoding a phenylalanine transporter, which are not naturally associated with the phenylalanine transporter gene and can be operably linked to a promoter that is directly or indirectly induceable; and c) one or more genes encoding mutant fumarate and nitrate reductase (FNR), which are not naturally associated with the FNR gene and can be operably linked to a promoter that is directly or indirectly induceable.

An IROA Matrix of metabolite compounds is disclosed. Each of whose compounds has a molecular weight of 2000 AMU or less, and is present as first and second isotopomers that are equally present at two predetermined isotopomeric balances, and contain 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. A reagent pair for transforming a natural abundance mass spectral analysis metabolite sample into an IROA sample is also disclosed and comprises two reactively identical reagents that constitute first and second isotopomers containing 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. Each of the reagent pair contains the same reactive group that reacts with and bonds to a functional group of one or more compounds present in a composition of biologically-produced metabolite compounds. Methods of making and using the above and related materials are also disclosed.

Provided are: a method which is for analyzing a neurogranin-related peptide and can suppress deviations in analysis results; and a method for preparing a biological sample containing the neurogranin-related peptide used for same. A method for preparing a sample solution containing a neurogranin-related peptide involves mixing a biological sample containing the neurogranin-related peptide with an organic solvent having a relative polarity of 0.200 to 0.700 to prepare a sample solution containing the organic solvent having a final concentration of at least 5.0 (v / v)%.

The invention relates to a method for analyzing a biological sample for changes in signatures of key metabolites in a hepatic disease, comprising (a) isolating erythrocytes from the biological sample, (b) identifying and optionally quantifying lipids from the erythrocytes as the key metabolites for a hepatic and infectious disease, including the lipids PC (28:0), PC (30:0), PC (30:1), PC (32:0), PC (32:1), PC (34:0), PC (34:1), PC (34:2), PC (36:0), PC (36:1), PC (36:2), PC (36:3), PC (36:4), PC (38:0), PC (38:1), PC (38:2), PC (38:3) and PC (38:4); SM (17:0), SM (12:0), SM (14:0), SM (16:0), SM (18:0), SM (18:1), SM (20:0), SM (22:0), SM (24:0), SM (24:1), SM (26:0) and SM (26:1); LPE (16:0), LPE (16:1), LPE (18:0), LPE (18:1), LPE (18:2) and LPE (20:4); Cer (15:0), Cer (12:0), Cer (14:0), Cer (16:0), Cer (18:0), Cer (18:1), Cer (20:0), Cer (22:0), Cer (24:0) and Cer (24:1); LPC (16:0), LPC (16:1), LPC (17:0), LPC (18:0), LPC (18:1), LPC (18:2), LPC (20:0), LPC (20:1), LPC (20:3) and LPC (20:4), and LPE (16:0), LPE (16:1), LPE (17:1), LPE (18:0), LPE (18:1), LPE (18:2) and LPE (20:4); (c) carrying out principal component analysis of the samples and clustering according to subgroups; (d) identifying key metabolites by means of XGBoost algorithm; (e) detecting the changes in the key signatures of the key metabolites of the hepatic disease identified in step (d), and (f) diagnosing a hepatic disease. The invention further relates to the use of the results of this method in personalized medicine.

The present disclosure provides methods and materials for screening a compound or monitoring a subject's response to a compound or dosing regimen for treating a PGRN-associated disorder. Methods and materials for identifying and treating a subject having a PGRN-associated disorder are also provided.

The present invention relates to a method for determining the sex of a fetus in an ungulate.

The invention relates to a panel of biomarkers, comprising or consisting of: benzene, benzothiazole, decane, isothiocyanato-cyclohexane, methylstyrene, phenol, styrene, toluene, 1-hexanol, 2-butoxyethanol, and p-xylene. In particular to the use of this panel in i) diagnosing eosinophilia in a subject, ii) treating an asthmatic subject with eosinophilia and / or who is suffering severe exacerbations, or iii) monitoring treatment efficacy in a subject with eosinophilia and / or who is suffering severe exacerbations.

The present invention describes a comprehensive system and method for the simultaneous early detection of multiple cancers in a single analysis. The system involves a Liquid Chromatography-Mass Spectrometry (LC-MS) device coupled with processors and AI / ML algorithms. The LC-MS device analyses metabolite ions from dried extracts of biological fluid samples, aligning and normalizing the data while minimizing errors. Quality control processes, including a neural network model and critical ion monitoring, ensure accurate detection. The system employs AI / ML processes to create two models: the Cancer Detection AI (CDAI) Model for identifying cancerous samples, and the Tissue of Origin Identification (TOOAI) Model for distinguishing specific cancer types. The models are applied to test samples, providing scores based on tissue of origin probabilities. The invention aims to revolutionize early cancer detection through advanced analytical and machine learning techniques.

The present invention describes a comprehensive system and method for the simultaneous early detection of multiple cancers in a single analysis. The system involves a liquid chromatography-mass spectrometry (LC-MS) instrument coupled with a processor and AI / ML algorithms. The LC-MS instrument analyzes metabolite ions from dried extracts of biological fluid samples and aligns and normalizes the data while minimizing errors. Quality control processes, including neural network models and critical ion monitoring, ensure accurate detection. The system employs an AI / ML process to create two models: a Cancer Detection AI (CDAI) model for identifying cancer samples and a Tissue of Origin Identification (TOOAI) model for distinguishing specific cancer types. These models are applied to test samples and provide a score based on tissue of origin probability. The present invention aims to revolutionize early cancer detection through advanced analytical and machine learning techniques.

The invention discloses a partial acylated non-natural sugar for metabolic labeling and application, the partial acylated non-natural sugar is a mannose type of a pyranose structure, and 1-hydroxyl and 6-hydroxyl are protected by hydrophobic groups. According to the method, the advantages of existing non-natural sugar are taken into consideration, it is guaranteed that the non-natural sugar can be efficiently utilized by cells, S side reaction of the non-natural sugar and cysteine in protein in the metabolism process is effectively avoided, and meanwhile efficient metabolism marking is achieved. In a cell test, the use concentration of the 1, 6-diacylated non-natural sugar is one order of magnitude lower than that of the non-natural sugar without the protecting group.

An anti-immunoglobulin specific antibody (or fragment thereof), characterised that the antibody or fragment thereof comprises one or more non-disulphide cross-links between at least one heavy chain or fragment thereof and at least one light chain or fragment thereof of the antibody or fragment thereof. A method purifying an anti-immunoglobulin specific antibody (or fragment thereof), characterised that the antibody or fragment thereof comprises one or more non-disulphide cross-links between at least one heavy chain or fragment thereof and at least one light chain or fragment thereof of the antibody or fragment thereof. A method of quantifying an amount of a subject analyte, or a fragment of an analyte in a sample from the subject comprising: (i) adding to the sample a predetermined amount of one or more control analytes or fragments thereof, which are distinguishable from the equivalent subject analyte or fragment; (ii) measuring the relative amount of the subject analyte or fragment and the amount of the control analyte or fragment in the sample; and (iii) comparing the relative amount of subject analyte or fragment to the relative amount of control analyte or fragment, to quantify the amount of analyte or fragment in the original subject sample.

Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.

The purpose of the present invention is to provide a method for evaluating the intestinal barrier function of a subject, the method comprising the steps of: (1a) measuring a biomarker in a subject derived from the subject, and acquiring a measured value of the biomarker; (1b) comparing the measured value obtained in step 1a with a reference value to obtain a comparison result; and (1c) a step for evaluating the intestinal barrier function of the subject on the basis of the comparison result obtained in step 1b, the subject being blood, serum or plasma, and the biomarker comprising one or more substances selected from the group of substances of the present invention.

A method of obtaining and processing a tear sample from an individual, including obtaining a sample of tears from an individual by use of a flexible tapered polymer structure having opening at a distal end thereof, the opening having a diameter of less than 1 millimeter and placing the distal end of the flexible tapered polymer structure into contact with the tears adjacent the eye and applying negative pressure to the flexible tapered polymer structure. The method further includes buffering the sample of tears by addition of a buffering solution, analyzing the sample of tears to identify cannabinoids within the sample of tears; and presenting results of analysis of the sample of tears.

A method for characterizing or quantifying one or more proteins in visible and / or sub-visible particles formed in a sample by detecting the at least one visible or sub-visible particle in the sample, isolating and capturing the at least one visible or sub-visible particle to identify a presence of a protein, and using a mass spectrometer to characterize the protein.

The present invention relates to a GRP78-derived peptide for screening highly efficient stem cells and the use thereof, and more particularly, to screening highly efficient stem cells using, as a marker, a GRP78-derived peptide capable of binding to the binding domain of GRP78 protein on the cell surface. According to the present invention, the GRP78-derived peptide comprising only a specific amino acid sequence capable of recognizing highly efficient stem cells, among the amino acid sequence of GRP78, makes it possible to screen only non-senescent young stem cells. In addition, when stem cells are treated with the GRP78-derived peptide or the GRP78-derived peptide is introduced into stem cells, the efficiency of the stem cells can be increased. Thus, the GRP78-derived peptide is useful for the production of stem cell therapy products having excellent efficacy.

The present disclosure may broadly provide a method for analysing analytes of interest comprising: a) mixing a biomaterial containing a protein target, with one or more candidate compounds for binding to the biomaterials to obtain a sample comprising one or more biomaterial-candidate complexes, b) introducing the sample to a mass spectrometer by ionising the sample under conditions that retain the one or more biomaterial-candidate complex in their native state, c) separating the one or more biomaterial-candidate complex from unbound candidate compounds by selecting for ions having a high mass range using a mass analyser configured to capture the one or more biomaterial-candidate complexes and excluding unbound candidate compounds based on a difference in oscillation frequencies of their respective ions, d) dissociating the biomaterial-candidate complex using collisional dissociation to obtain one or more dissociated candidate compounds, and e) determining the dissociated candidate compound based on mass-to-charge ratio (m / z).

Immunohistochemistry (INC) and in situ hybridization (ISH) methods are used for the targeted detection and localization of biomolecules (e.g., proteins and miRNAs) in tissues or cells, for research applications and clinical applications such as those of pathologists (e.g., biomarker analysis of resected tumors or tumor biopsies). These methods include mass spectrometry imaging (MSI) as a mode for detecting and localizing biomolecules in tissues or cells. The methods employ optically cleavable mass-tagged reagents linked to probes such as antibodies and nucleic acids and used to enable multiplexed immunohistochemistry and in situ hybridization, with MSI as the detection / readout mode. The methods also include multi-omics MSI procedures in which MSI of optically cleavable mass-tagged probes is combined with other MSI modes, such as direct label-free MSI of endogenous biomolecules from biological samples (e.g., tissues).

The present invention comprises a method for determining the biological age of an animal, wherein the method comprises determining the level of at least one biomarker in said animal, and wherein the at least 1 biomarker is selected from the biomarkers as listed in Table 1.

[Problem] To provide a highly reliable method for evaluating the risk of the occurrence of NAFLD, and a biomarker used therein. [Solution] A method for evaluating the risk of occurrence of a non-alcoholic fatty liver disease, said method comprising: an acquisition step for acquiring a sample derived from a body fluid of a subject; a detection step of detecting 14 kinds of compounds including lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, alpha-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid and tryptophan in the sample; and a use step for using all of the 14 types of detection quantities obtained by the detection step.

In a general aspect, methods and devices for using mass spectrometry to identify endometriosis are provided.SOLUTION: In some embodiments, a fixed or discrete volume of solvent is applied to the tissue site containing the potential endometriotic tissue. The applied solvent is collected to obtain a liquid sample. The liquid sample is subjected to mass spectrometry. The fluid sample is retrieved from a tissue site in vivo during a medical procedure. The mass spectrometry data is analyzed to identify whether the tissue site contains endometriosis.SELECTED DRAWING: Figure 2

Described herein are reagents and methods for improving signal in imaging mass cytometry. Aspects include mass tags with a large number of labeling atoms, chemical modifications to mass tags and additional reagents to reduce background and / or maintain target binding of mass tagged specific binding partners (SBPs), and schemes for associating a plurality of mass tags with a single SBP. As such, embodiments include any combination of one or more reagents and their use. The reagents, kits and methods herein may be used for mass cytometry, including imaging mass cytometry. In some aspects, reagents, kits or methods may be used for delivery of a large number of radioisotopes to a target analyte, for example for therapeutic use or radiometric detection. In certain aspects, only non-radioactive isotopes may be used for mass cytometry.

The invention provides a method for detecting one or more analytes, the method comprising: providing a substrate comprising a semiconductor with a porous surface, wherein the porous surface is coated with a fluorocarbon polymeric coating; contacting the porous surface with a fluid or object so that the one or more analytes are retained on the substrate when present in the fluid or on the object; and analysing the substrate by mass spectrometry to detect the one or more analytes if present on the substrate.